Journal
CURRENT OPINION IN VIROLOGY
Volume 38, Issue -, Pages 1-9Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2019.03.004
Keywords
-
Categories
Funding
- National Health and Medical Research Council (NHMRC) of Australia
- National Institutes of Health [UM lAI126611]
- American Foundation for AIDS Research [amfAR 109226-58-RGRL]
Ask authors/readers for more resources
Latently infected cells that persist in HIV-infected individuals on antiretroviral therapy (ART) are a major barrier to cure. One strategy to eliminate latency is by activating viral transcription, commonly called latency reversal. Several small non-randomised clinical trials of latency reversing agents (LRAs) in HIV-infected individuals on ART increased viral production, but disappointingly did not reduce the number of latently infected cells or delay time to viral rebound following cessation of ART. More recent approaches aimed at reversing latency include compounds that both activate virus and also modulate immunity to enhance clearance of infected cells. These immunomodulatory LRAs include toll-like receptor agonists, immune checkpoint inhibitors and some cytokines. Here, we provide a brief review of the rationale for transcription-activating and immunomodulatory LRAs, discuss recent clinical trials and some suggestions for combination approaches and research priorities for the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available